This study is currently not recruiting participants.

Serial Fecal Biomarker Measurements in Patients Receiving Remicade- ASCAIII

Investigating Changes in Pediatric Crohn's Disease and Ulcerative Colitis

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to assess the change in Fecal and serum biomarkers over time in pediatric patients with Crohn Disease, and Ulcerative Colitis initiating therapy with Remicade.

Detailed description of study

The purpose of this study is to assess the change in Fecal and serum biomarkers over time in pediatric patients with Crohn Disease, and Ulcerative Colitis initiating therapy with Remicade.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ulcerative colitis,Crohn's disease
  • Age: 100 years or below
  • Gender: All

This study investigates the changes in fecal and serum biomarkers in children with Crohn's Disease and Ulcerative Colitis. Biomarkers are substances used to see how well the body responds to a treatment. This study focuses on children starting treatment with an investigational medication.

Participants will have their blood and stool samples tested to monitor these biomarkers. This helps researchers understand how the body is responding to the treatment over time.

  • Who can participate: Participants are children aged X to Y diagnosed with Crohn's Disease or Ulcerative Colitis who are beginning treatment with an investigational medication.
  • Study details: Participants will provide blood and stool samples for testing. A placebo is not used in this study.
Updated on 19 Feb 2024. Study ID: 1706103792

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team